RxDoctor Payments Data

Carissa Parnell, APRN

Family · Anderson, SCNPI 1861826190

Payments from drug & device makers

$1,927in general payments, 2019–2025

Across 91 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$712
  • Otsuka America Pharmaceutical, Inc.$302
  • Teva Pharmaceuticals USA, Inc.$147
  • Ironshore Pharmaceuticals Inc.$144
  • Axsome Therapeutics, Inc.$118
  • Sunovion Pharmaceuticals Inc.$79
  • plus $426 from 10 others

What the payments were for

  • Food & beverage$1,927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,927 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$8,258
Medicare patients
25
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$93,211
RexultiBrexpiprazole21$35,127
VraylarCariprazine Hcl11$18,522
Invega SustennaPaliperidone Palmitate12$13,322
TrintellixVortioxetine Hydrobromide15$10,347
Asenapine Maleate21$5,851
VyvanseLisdexamfetamine Dimesylate12$4,690
Oxcarbazepine97$3,903
Duloxetine Hcl107$3,803
Aripiprazole92$3,735
Fluvoxamine Maleate92$3,370
Ziprasidone Hcl44$2,678
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine75$2,075
Trazodone Hcl184$1,908
Clonazepam213$1,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$67$93,21112 claims
Otsuka America Pharmaceutical, Inc.Rexulti$302$35,12721 claims
AbbVieVraylar$712$18,52211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$46$15,03727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →